Bicycle Therapeutics (BCYC) to Release Quarterly Earnings on Tuesday

Bicycle Therapeutics (NASDAQ:BCYC) is expected to be announcing its earnings results before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.88) per share and revenue of $5.47 million for the quarter.

Bicycle Therapeutics Trading Down 2.8 %

Shares of Bicycle Therapeutics stock opened at $11.84 on Tuesday. Bicycle Therapeutics has a 1-year low of $11.77 and a 1-year high of $28.67. The firm’s 50-day moving average price is $14.89 and its two-hundred day moving average price is $20.43. The stock has a market capitalization of $817.50 million, a price-to-earnings ratio of -3.60 and a beta of 0.93.

Insider Transactions at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 9,038 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares of the company’s stock, valued at approximately $6,974,916.34. This represents a 1.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the transaction, the chief accounting officer now directly owns 32,146 shares in the company, valued at $482,190. This trade represents a 7.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Stephens reissued an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. B. Riley dropped their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price objective on shares of Bicycle Therapeutics in a report on Monday, January 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Bicycle Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $33.25.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.